DÄ internationalArchiveReferences
References

Clinical Practice Guideline

Lyme Neuroborreliosis

Dtsch Arztebl Int 2018; 115: 751-6. DOI: 10.3238/arztebl.2018.0751

Rauer, S; Kastenbauer, S; Fingerle, V; Hunfeld, K; Huppertz, H; Dersch, R

1. Dersch R, Toews I, Sommer H, et al.: Methodological quality of guidelines for management of Lyme neuroborreliosis. BMC Neurol 2015; 15: 242 CrossRef MEDLINE PubMed Central
2. Dersch R, Freitag MH, Schmidt S, et al.: Efficacy and safety of pharmacological treatments for neuroborreliosis—protocol for a systematic review. Syst Rev 2014; 3: 117 CrossRef MEDLINE PubMed Central
3. Dersch R, Freitag MH, Schmidt S, et al.: Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis—a systematic review. Eur J Neurol 2015; 22: 1249–59 CrossRef MEDLINE
4. Rauer S, Kastenbauer S, et al.: S3 Leitlinie Neuroborreliose. Deutsche Gesellschaft für Neurologie (ed.) 2018. Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien.
5. Oschmann P, Dorndorf W, Hornig C, et al.: Stages and syndromes of neuroborreliosis. J Neurol 1998; 245: 262–72 CrossRef MEDLINE
6. Hansen K, Lebech AM: The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study
of 187 patients with borrelia burgdorferi specific intrathecal antibody production. Brain 1992; 115: 399–423 CrossRef MEDLINE
7. Kaiser R: Variable CSF findings in early and late Lyme neuroborreliosis: a follow-up study in 47 patients. J Neurol 1994; 242: 26–36 CrossRef
8. Djukic M, Schmidt-Samoa C, Lange P, et al.: Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol 2012; 259: 630–6 CrossRef MEDLINE PubMed Central
9. Kristoferitsch W, Sluga E, Graf M, et al.: Neuropathy associated with acrodermatitis chronica atrophicans. Clinical and morphological features. Ann N Y Acad Sci 1988; 539: 35–45 CrossRef MEDLINE
10. Kindstrand E, Nilsson BY, Hovmark A, et al.: Peripheral neuropathy in acrodermatitis chronica atrophicans—a late borrelia manifestation. Acta Neurol Scand 1997; 95: 338–45 CrossRef MEDLINE
11. Mygland A, Skarpaas T, Ljostad U: Chronic polyneuropathy and Lyme disease. Eur J Neurol 2006; 13: 1213–5 CrossRef MEDLINE
12. Hess A, Buchmann J, Zettl UK, et al.: Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenialike disorder. Biol Psychiatry 1999; 45: 795 CrossRef
13. Christen HJ: Lyme neuroborreliosis in children. Ann Med 1996; 28: 235–40 CrossRef
14. Huppertz HI, Sticht-Groh V: Meningitis due to borrelia burgdorferi in the initial stage of Lyme disease. Eur J Pediatr 1989; 148: 428–30 CrossRef
15. Huppertz HI, Bartmann P, Heininger U, et al.: Rational diagnostic strategies for Lyme borreliosis in children and adolescents: recommendations by the Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health. Eur J Pediatr 2012; 171: 1619–24 CrossRef MEDLINE PubMed Central
16. Halperin JJ, Logigian EL, Finkel MF, Pearl RA: Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996; 46: 619–27 CrossRef
17. Fingerle V, Eiffert H, Gessner A, et al.: Lyme borreliose. In: Podbielski A, Abele-Horn M, Hermann M, Kniehl E, Mauch H, Rüssmann H (eds.): MiQ – Qualitätsstandars in der mikrobiologisch-infektiologischen Untersuchung. 2nd edition. München, Jena: Elsevier, Urban & Fischer 2017.
18. Stanek G, Fingerle V, Hunfeld KP, et al.: Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17: 69–79 CrossRef MEDLINE
19. Wilske B, Fingerle V, Schulte-Spechtel U: Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol 2007; 49: 13–21 CrossRef MEDLINE
20. Ljostad U, Skarpaas T, Mygland A: Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis. Eur J Neurol 2007; 14: 873–6 CrossRef MEDLINE
21. Reiber H, Peter JB: Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184: 101–22 CrossRef
22. Kaiser R: Neuroborreliosis. J Neurol 1998; 245: 247–55 CrossRef
23. Dessau RB, Fingerle V, Gray J, et al.: The lymphocyte transformation test for the diagnosis of Lyme borreliosis has currently not been shown to be clinically useful. Clin Microbiol Infect 2014; 20: O786-7 CrossRef MEDLINE
24. Lantos PM, Auwaerter PG, Wormser GP: A systematic review of borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease. Clin Infect Dis 2014; 58: 663–71 CrossRef MEDLINE PubMed Central
25.Jowett N, Gaudin RA, Banks CA, Hadlock TA: Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope 2017; 127: 1451–8 CrossRef MEDLINE
26.Oksi J, Nikoskelainen J, Hiekkanen H, et al.: Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis 2007; 26: 571–81 CrossRef MEDLINE
27. Pfister HW, Preac-Mursic V, Wilske B, et al.: Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991; 163: 311–8 CrossRef MEDLINE
28. Ogrinc K, Lusa L, Lotric-Furlan S, et al.: Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings. Clin Infect Dis 2016; 63: 346–53 CrossRef MEDLINE
29. Kaiser R: [Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone]. Nervenarzt 2004; 75: 553–7 CrossRef MEDLINE
30. Berglund J, Stjernberg L, Ornstein K, et al.: 5-y follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002; 34: 421–5 CrossRef MEDLINE
31. Dersch R, Hottenrott T, Schmidt S, et al.: Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review. BMC Neurol 2016; 16: 189 CrossRef MEDLINE PubMed Central
32. Koedel U, Fingerle V, Pfister HW: Lyme neuroborreliosis-epidemiology, diagnosis and management. Nat Rev Neurol 2015; 11: 446–56 CrossRef MEDLINE
33. Halperin JJ: Nervous system Lyme disease. Infect Dis Clin North Am 2015; 29: 241–53 CrossRef MEDLINE
34. Feder HM, Jr., Johnson BJ, O‘Connell S, et al.: A critical appraisal of „chronic Lyme disease“. N Engl J Med 2007; 357: 1422–30 CrossRef MEDLINE
35. Dersch R, Sommer H, Rauer S, Meerpohl JJ: Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol 2016; 263: 17–24 CrossRef MEDLINE
36. Klempner MS, Hu LT, Evans J, et al.: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85–92 CrossRef MEDLINE
37. Fallon BA, Keilp JG, Corbera KM, et al.: A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70: 992–1003 CrossRef MEDLINE
38. Krupp LB, Hyman LG, Grimson R, et al.: Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60: 1923–30 CrossRef MEDLINE
39. Kaplan RF, Trevino RP, Johnson GM, et al.: Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003; 60: 1916–22 CrossRef MEDLINE
e1. Patel R, Grogg KL, Edwards WD, et al.: Death from inappropriate therapy for lyme disease. Clin Infect Dis 2000; 31: 1107–9 CrossRef MEDLINE
e2. Holzbauer SM, Kemperman MM, Lynfield R: Death due to community-associated clostridium difficile in a woman receiving prolonged antibiotic therapy for suspected lyme disease. Clin Infect Dis 2010; 51: 369–70 CrossRef MEDLINE
e3. Marzec NS, Nelson C, Waldron PR, et al.: Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic lyme disease—United States. MMWR Morb Mortal Wkly Rep 2017; 66: 607–9 CrossRef MEDLINE PubMed Central
e4. Wilking H, Stark K: Trends in surveillance data of human lyme borreliosis from six federal states in eastern Germany, 2009–2012. Ticks Tick Borne Dis 2014; 5: 219–24 CrossRef MEDLINE
e5. Muller I, Freitag MH, Poggensee G, et al.: Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: a retrospective model analysis. Clin Dev Immunol 2012; 2012: 595427 CrossRef MEDLINE PubMed Central
e6. Kaiser R, Kern A, Kampa D, Neumann-Haefelin D: Prevalence of antibodies to borrelia burgdorferi and tick-borne encephalitis virus in an endemic region in southern Germany. Zentralbl Bakteriol 1997; 286: 534–41 CrossRef
e7. Stanek G, Flamm H, Groh V, et al.: Epidemiology of borrelia infections in Austria. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 263: 442–9 CrossRef
e8. Wilking H, Fingerle V, Klier C, et al.: Antibodies against borrelia burgdorferi sensu lato among adults, Germany, 2008–2011. Emerg Infect Dis 2015; 21: 107–10 CrossRef MEDLINE PubMed Central
e9. Heininger U, Zimmermann T, Schoerner C, et al.: Zeckenstich und Lyme-Borreliose – Eine epidemiologische Untersuchung im Raum Erlangen. Monatsschrift Kinderheilkunde 1993; 141: 874–7.
e10. Maiwald M, Oehme R, March O, et al.: Transmission risk of borrelia burgdorferi sensu lato from Ixodes ricinus ticks to humans in southwest Germany. Epidemiol Infect 1998; 121: 103–8 CrossRef MEDLINE PubMed Central
e11. Paul H, Gerth HJ, Ackermann R: Infectiousness for humans of Ixodes ricinus containing borrelia burgdorferi. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology 1987; 263: 473–6 CrossRef MEDLINE
e12. Henningsson AJ, Malmvall BE, Ernerudh J, et al.: Neuroborreliosis – an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden. Clin Microbiol Infect 2010; 16: 1245–51 CrossRef
e13. Hassler D, Zoller L, Haude M, et al.: [Lyme borreliosis in an endemic region in Europe. Prevalence of antibodies and clinical spectrum]. Dtsch Med Wochenschr 1992; 117: 767–74 CrossRef MEDLINE
e14. Pasareanu AR, Mygland A, Kristensen O: A woman in her 50s with manic psychosis. Tidsskr Nor Laegeforen 2012; 132: 537–9 MEDLINE
e15. Roelcke U, Barnett W, Wilder-Smith E, et al.: Untreated neuroborreliosis: Bannwarth‘s syndrome evolving into acute schizophrenia-like psychosis. A case report. J Neurol 1992; 239: 129–31 CrossRef MEDLINE
e16. Markeljevic J, Sarac H, Rados M: Tremor, seizures and psychosis as presenting symptoms in a patient with chronic lyme neuroborreliosis (LNB). Coll Antropol 2011; 35, Suppl 1: 313–8.
e17. Csaszar T, Patakfalvi A: [Differential diagnostic problems in lyme disease (Borrelia infection resulting in acute exogenous psychosis)]. Orv Hetil 1994; 135: 2269–71 MEDLINE
e18. Wittwer B, Pelletier S, Ducrocq X, et al.: Cerebrovascular events in lyme neuroborreliosis. J Stroke Cerebrovasc Dis 2015; 24: 1671–8 CrossRef MEDLINE
e19. Zajkowska J, Garkowski A, Moniuszko A, et al.: Vasculitis and stroke due to lyme neuroborreliosis—a review. Infect Dis (Lond) 2015; 47: 1–6 CrossRef MEDLINE
e20. Schmutzhard E, Willeit J, Gerstenbrand F: Meningopolyneuritis Bannwarth with focal nodular myositis. A new aspect in lyme borreliosis. Klin Wochenschr 1986; 64: 1204–8 CrossRef MEDLINE
e21. Reimers CD, de Koning J, Neubert U, et al.: Borrelia burgdorferi myositis: report of eight patients. J Neurol 1993; 240: 278–83 CrossRef MEDLINE
e22. Wilke M, Eiffert H, Christen HJ, Hanefeld F: Primarily chronic and cerebrovascular course of lyme neuroborreliosis: case reports and literature review. Arch Dis Child 2000;83:67–71 CrossRef PubMed Central
e23. Nordberg M, Forsberg P, Nyman D, et al.: Can ELISPOT be applied to a clinical setting as a diagnostic utility for neuroborreliosis? Cells 2012; 1: 153–67.
e24. Marques A, Telford SR, III, Turk SP, et al.: Xenodiagnosis to detect borrelia burgdorferi infection: a first-in-human study. Clin Infect Dis 2014; 58: 937–45 CrossRef MEDLINE PubMed Central
e25. Bockenstedt LK, Radolf JD: Xenodiagnosis for posttreatment lyme disease syndrome: resolving the conundrum or adding to it? Clin Infect Dis 2014; 58: 946–8 CrossRef MEDLINE PubMed Central
e26. Hartmann F, Mueller-Marienburg H: Indirekter Neurotoxinnachweis durch den „Visual Contrast Sensitivity“-Test bei Patienten mit einer chronischen Borreliose. Die Medizinische Welt – aus der Wissenschaft in die Praxis 2003; 54: 248–51.
e27. Stricker RB, Winger EE: Decreased CD57 lymphocyte subset in patients with chronic lyme disease. Immunology Letters 2001; 76: 43–8 CrossRef
e28. Smit PW, Kurkela S, Kuusi M, Vapalahti O: Evaluation of two commercially available rapid diagnostic tests for lyme borreliosis. Eur J Clin Microbiol Infect Dis 2015; 34: 109–13 CrossRef MEDLINE
e29. Klempner MS, Baker PJ, Shapiro ED, et al.: Treatment trials for post-lyme disease symptoms revisited. Am J Med 2013; 126: 665–9 CrossRef MEDLINE PubMed Central
e30. Brouwers MC, Kho ME, Browman GP, et al.: AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 2010; 51: 421–4 CrossRef MEDLINE
e31. Mygland A, Ljostad U, Fingerle V, et al.: EFNS guidelines on the diagnosis and management of European lyme neuroborreliosis. Eur J Neurol 2009.
e32. Halperin JJ, Shapiro ED, Logigian E, et al.: Practice parameter: treatment of nervous system lyme disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2007; 69: 91–102 CrossRef MEDLINE
e33. Rauer S, Kaiser R, Kölmel HW, et al.: Neuroborreliose. In: Diener HC, Weimar C (eds.): Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, New York: Georg Thieme Verlag 2012: 513–22.
e34. Balshem H, Helfand M, Schunemann HJ, et al.: GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol 2011; 64: 401–6 CrossRef MEDLINE